Our aim was to evaluate the number of progenitor cells circulating in an ␣-thalassemic fetus during its infusion in utero with paternal CD34 + and adult red cells and to compare those values with those circulating in normal and non-thalassemic anemic fetuses of matched gestational age. The treatment of the ␣-thalassemic fetus has been described elsewhere. Fetal blood was obtained from normal and anemic fetuses by fetal blood sampling for diagnostic or therapeutic purposes according to a protocol approved by the human subject committee. The number of progenitor cells in fetal blood was estimated on the basis of the number of colonies they gave rise to in semisolid cultures. The ␣-thalassemic fetus, as did the other fetuses analyzed, contained high numbers (10 6 -10 7 depending on the age) of progenitor cells, values which were higher than the number (10 4 -10 5 ) of paternal progenitor cells being transplanted. Progenitor cells with adult characteristics (adult kinetics of differentiation) were detected rapidly (10 min) after the CD34 + cell infusion, but were not detectable 2-3 weeks after the transplant. These results indicate that adult progenitor cells do not have a numerical advantage when transplanted into ␣-thalassemic fetuses.
land, 2 ␥ 2 ). 1 In contrast, definitive erythroid cells, which circulate from 10 to 30 weeks gestation, synthesize mainly fetal Hb (Hb F, ␣ 2 ␥ 2 ), together with a small component (10-15%) of adult Hb (Hb A, ␣ 2 ␤ 2 ). At birth, approximately equal amounts of Hb A and Hb F are synthesized and the final adult erythroid pattern (adult Hb with Ͻ1% fetal Hb) is reached a few months after birth (reviewed in Ref. 2) .
␣-Thalassemia (␣-thal) is a genetic disorder caused by mutations in one or more of the four alleles that encode the ␣chain of hemoglobin Hb (two alleles on each of the chromosome 16) (reviewed in Ref. 3) . The most severe of these disorders (␣-thal-1) is caused by deletion of all the four ␣globin genes. As a consequence, ␣thal-1 fetuses do not synthesize any ␣chains and their red cells contain, from approximately 10 weeks gestation, Hb Barts, a tetramer of ␤-globin chains, which does not transport O 2 efficiently. Therefore, unlike ␤-thalassemia in which clinical manifestations occur after birth, ␣-thal-1 leads to hydrops fetalis often resulting in spontaneous abortion or pre-term birth between 16 and 36 weeks of gestation. Liveborn infants often have significant neurological deficits due to chronic in utero hypoxia.
The recent improvements in ultrasound-guided chorionic villous biopsy and molecular PCR genotyping have made it possible to diagnose genetic defects in the first trimester of pregnancy. In cases of fetuses affected with ␣-thal-1 when the parents opt to continue the pregnancy, some have advocated intrauterine fetal red cell transfusions in an attempt to prevent the neurodevelopmental problems mentioned above. [4] [5] [6] [7] The success of this treatment depends on how early the transfusions are begun and how frequently they are repeated. Since in the case of ␣-thal-1, fetal anemia (and, thus hypoxia) can occur as early as the end of the first trimester, any attempt to prevent the hypoxia-induced neurodevelopmental problems by in utero red cell transfusion should begin at the end of the first or beginning of the second trimester and the frequency of transfusions should be sufficient to prevent significant fetal anemia.
The successful treatment of SCID by in utero transplantation, 8, 9 had suggested that this therapy could be more effective than conventional post-natal bone marrow transplantation for all those genetic diseases, including ␣-thal-1, that can be cured with such treatment. 10 In fact, not only could it effect a cure before the phenotypic manifestations of the disease have occurred, but might also be safer than 'conventional' bone marrow transplantation because the fetus is immunologically immature and, therefore, less likely to reject the transplant. In addition, it will obviate the need for the myelosuppressive regimen necessary for post-natal engraftment, which is responsible for most of the morbidity of the therapy.
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Based on these assumptions, in 1995 a fetus with ␣-thal-1 was treated by intrauterine red cell and paternal CD34 + cells transfusion 7 in Denver and in New York, under a protocol approved by the institutional Human Subjects Committee, the National Heart Lung and Blood Institute, and Food and Drug Administration of the United States of America. The red cell transfusions did indeed prevent abnormal neurological development. Microchimerism, however, was detected in the fetus soon after the paternal CD34 + cell transfusion, but full engraftment never occurred. More recently, it has became evident that even in the case of the SCID fetuses transplanted in utero, 8, 9 the donor stem cells did not engraft and only the mature T cells were of donor origin. It is debated whether the lack of engraftment in utero transplantation is due to lack of space in the developing hemopoietic organs or to rejection of the donor cells by the recipient's immune system (ie NK cells).
Here we compare the number of paternal progenitor cells (CFC) transplanted with the number of fetal CFC in the circulation at the time of treatment or, when sampling of the fetal blood had not been possible, with the CFC numbers observed in non-thalassemic fetuses (anemic and nonanemic) of comparable gestational age. The results indicate that the paternal CD34 + cells transplanted in utero did not have a numerical advantage over the number of cells already circulating in the fetus.
Materials and methods

Human subjects
The treatment of the homozygous ␣-thal-1 male fetus is described in detail in Ref. 7 , and is briefly summarized in Table 1 . Age-matched controls were represented by patients referred to the Prenatal Diagnosis Unit at the New York Hospital-Cornell Medical center for fetal blood sampling (a total of 31 specimens from 17-39-week-old fetuses) for either diagnostic (two suspected fetal infection, one HLA typing, seven at risk of genetic disorders such as trisomy 8, 13 and 21 or Fanconi anemia) or therapeutic (four alloimmune thrombocytopenia and 17 red blood cell alloimmunization) purposes. In these cases, fetal blood sampling was performed from the umbilical vein at the insertion of the umbilical cord into the placenta under continuous ultrasound guidance with a 20-or a 22-gauge needle as described. 12 This technique is reasonably safe when performed after 17 weeks of gestation. 13 The blood from four younger fetuses (12-13 weeks old) was obtained from the heart just before first trimester multifetal pregnancy reduction. The blood was confirmed to be fetal in origin by comparison of the fetal erythrocyte mean cell volume with that of the mother. Further controls were represented by blood from adults (the mother and the father of the ␣-thal-1 patient), from a 2-month-old normal infant and from 20 full-term delivery cord bloods. Permission to obtain fetal blood was granted through informed consent and approved by the Institutional Review Board.
Progenitor cell assay
A standardized progenitor cell assay (variance between blind replicate determination of the same sample Ͻ10%) was developed as part of the Placental/Cord Blood for Transplantation Program of the New York Blood Center 14 and was used here for the evaluations of progenitor cells in fetal blood. Aliquots (5 and 10 l) of fetal, perinatal and post-natal blood were directly mixed with standardized ready-to use semisolid methylcellulose (0.8% wt/v, Eastman-Kodak, Rochester, NY, USA) media (2.4 ml per tube) dissolved in Iscove's modified Dulbecco's medium (Gibco, Grand Island, NY, USA) containing fetal bovine serum (30% v/v, Gemini BioProd, Calabasas, CA, USA) and deionized albumin (1% v/v, Sigma, St Louis, MO, USA), 7.5 ϫ 10 Ϫ5 m ␤-mercaptoethanol (Sigma) and 1% (vol/vol) antibiotic-antimycotic solution (penicillin, streptomycin, fungizone, Gibco). The cultures were stimulated with a mixture of pure recombinant human growth factors including stem cell factor (SCF, 10 ng/ml), interleukin 3 (IL-3, 2 ϫ 10 Ϫ10 mol/l), granulocyte-macrophage colony-stimulating factor (GM-CSF, 4.5 ϫ 10 Ϫ10 mol/l), granulocyte colony-stimulating factor (G-CSF, 2 ϫ 10 Ϫ10 mol/l) and erythropoietin (EPO, 1.5 U/ml). The growth factors were a gift from Amgen (Thousand Oaks, CA, USA) and Genetics Institute (Cambridge, MA, USA). Each culture was analyzed in duplicate (1 ml/35-mm dish) and incubated at 37ºC in a 5% CO 2 /O 2 atmosphere until scoring. The number of colonies containing Ͼ500 cells was enumerated by eye with the help of an inverted microscope according to standard morphological criteria. 15 Erythroid, granulo-monocytic and mixed (granulocytic and erythroid) colonies were scored individually, but their number was pooled in this analysis because it had been previously shown that, in the case of cord blood transplantation, the total colony number correlates with the speed of engraftment. 14 
Globin chain content determination
The globin chain content of fetal and adult blood was analyzed by triton urea electrophoresis as previously described by Alter et al. 16 
Statistical analysis
Analysis of variance (Anova test) and regression analysis was performed with Origin 3.5 for Windows (Microcal Software Inc, Northampton, MA, USA). 
Results
Circulating progenitor cells in normal and anemic nonthalassemic fetuses
The number of progenitor cells circulating in human fetuses of increasing gestational age is presented in Figure 1 . The blood of normal fetuses, and of fetuses sampled for hemopoietic disorders whose Hct values were normal, contained a relatively constant number of progenitor cells (60 Ϯ 13 CFC/l of blood) although a tendency, which did not reach statistical significance, toward a decrease in CFC content with gestational age was observed (Figure 1) . The blood of five of the eight anemic non-thalassemic fetuses analyzed, contained a number of CFC per l higher than the blood of normal fetuses of comparable gestational age. On average, the difference in the number of circulating progenitor cells in normal and anemic non-thalassemic fetuses (140 Ϯ 20 CFC/l of blood) was statistically significant (P Ͻ 0.01). Since the increase in blood volume during human ges- 
Globin chain content of RBC and numbers of circulating progenitor cells in the ␣-thalassemia patient
The ␣-thal-1 fetus was transfused on several occasions with packed normal red cells and transplanted at 14, 19 and 23 weeks of age with paternal CD34 + cells (see Table 1 ). The Hb Barts content of its blood during these transfusions was previously described. 7 For practical (i.p. and not i.v. site of injection) and ethical (sampling of blood from a small fetus for reasons not strictly linked to its well-being) reasons, blood was not available for this study before 23 weeks of gestation. The globin chain content of the fetal blood at 23, 27, 30 and 34 weeks was further analyzed in this study by triton urea electrophoresis (not shown) and the globin chain ratios obtained are summarized in Table  1 . The injection of adult red cells maintained the ␣/non-␣ ratio between 37 and 59%, against ratios observed in the blood of normal fetuses of 75-95%. Another indicator that adult red cells were circulating in the fetus is represented by the ␤/␤+␥ ratio which remained between 35 and 60%, values significantly higher than those expressed by red cells from fetuses of comparable age (from 5 to 35%, depending on the age). Figure 2 shows the number of total nucleated cells per ml of blood and the frequency of progenitor cells per l and per 10 4 mononuclear cells in the blood of the ␣-thal-1 fetus.
At 23 weeks, the blood of the ␣-thal-1 fetus contained 20 times fewer mononuclear cells than normal fetuses (Ͻ10 5 per ml vs the 2 ϫ 10 6 found in the blood of normal fetuses). The number of total nucleated cells significantly increased, (Ͼ5 ϫ 10 5 cells per ml) at 30 and 34 weeks, just before birth. Soon after birth, following a double exchange transfusion (Table 1) , the mononuclear blood cell counts became very low to return to normal values 2 weeks after birth (Figure 2) .
Bone Marrow Transplantation
The frequency of progenitor cells per l of blood remained consistently two-fold lower than those observed in normal fetuses (Figure 2, middle panel) . This frequency dramatically increased around birth (ෂ100 CFC/l of blood) (Figure 2 Fetal and adult progenitor cells mature in vitro with different kinetics, as determined on the basis of the day of culture in which maximal number of colonies are scored and optimal levels of globin chains are synthesized by the cells within the colonies: maximal number of fetal colonies and of globin chain incorporation are detected as early as 8-10 days after the initiation of the culture. 15, 18, 19 In contrast, adult colonies, whose presence is below detectable levels on day 10, undergo optimal growth as late as at day 14-16 of culture. 20 Although it is theoretically possible to discriminate between recipient's and donor's CFC circulating in the fetal blood by single colony PCR genotyping (either for the HLA 7 or for the ␣-globin 21 locus), these experiments are not trivial and involve numerous PCR reactions. Therefore, fetal and adult progenitor cells were discriminated in this study on the basis of their different kinetics of maturation. At 23 weeks, the blood of the ␣-thal-1 fetus, that had been transfused 4 weeks earlier with paternal CD34 + cells, was sampled either before or 15 min after the injection of additional paternal CD34 + cells (Table 1) . No difference was observed in the number of CFC which grew at 10 or at 15 days in cultures of blood harvested before the transfusion (ෂ550 colonies/10 4 nucleated cells in both cases). In contrast, two-fold more colonies were scored at day 15 than at day 10 in cultures of blood sampled after the transfusion (ෂ250 vs 600 colonies/10 4 nucleated cells, respectively). Furthermore, while the erythroid colonies from the ␣-thal-1 fetus are usually small and pale, many of the erythroid colonies observed at day 15 in cultures of blood harvested after the transfusion were large and bright red. These results suggest that at least 50% of the progenitor cells circulating 15 min after the transfusion were of adult origin.
Discussion
In utero stem cell transplantation therapy is potentially more effective than conventional post-natal bone marrow transplantation for those genetic diseases that can be cured with such treatment. In fact, it could effect a cure before the phenotypic manifestations of the disease have occurred and might be safer than 'conventional' bone marrow trans- The values in parenthesis are calculated from those measured in normal fetuses (Figure 1 ) on the assumption that, as observed later on in development, the blood from the ␣-thal-1 fetus contains a total number of CFC similar to the number contained in the blood of the normal ones. b Calculated from the number of paternal cells transfused (Table 1 ) based on the assumption that the cloning efficiency of adult CD34 + cells is either 10%, as observed in our laboratory, 22 or 1.7%, as observed in the laboratory of the investigators that developed the method to purify the cells used in this study. 33 plantation because it does not require the myelosuppressive regimen necessary for post-natal engraftment, which is responsible for most of the morbidity of this therapy. 10, 11 In addition, the immunologically immature fetuses may be less likely to reject the transplant, thus improving chances for engraftment.
Several models of marrow engraftment without myelosuppression have been recently developed in mice. 23 Engraftment under such conditions is achieved when the transplanted cells have either (1) 27 and the need for fewer growth factors to achieve optimal differentiation in vitro (a single vs at least three to four growth factors). Each one of those differences could provide either an advantage or disadvantage to the adult cells with respect to the fetal ones and adult cells will ultimately compete with the fetal ones depending on the balance established among all of those differences in vivo, a balance hardly predictable on a theoretical basis. On the other hand, the small size of the recipient supports the notion that adult cells might have a numerical advantage when transplanted in utero. Because of the limited number of stem cell niches that may became available in a fetus, the ratio between the number of adult cells injected and the number of the corresponding fetal cells already present in the circulation may represent one of the most important factors for the efficient engraftment of adult cells in a fetus.
Several investigators have shown that the human fetal blood contains high numbers of progenitor cells, either phenotypically defined as CD34
+ cells or functionally defined as CFC. 12, 28, 29 The number of progenitor cells calculated according to both definitions correlates with the number of repopulating cells in humans: the CD34 + content predicts the engraftment of adult grafts, 30 while the CFC content predicts the outcome of transplants with umbilical/cord blood grafts.
14 However, the total number of hemopoietic progenitor cells, either CD34
+ or CFC, present in fetal blood during ontogenesis has never been calculated.
Since in the mouse, expression of CD34 is acquired by the marrow repopulating cells only after birth, 31 and in humans the CFC frequency in newborn blood correlates with the frequency of a fraction of all the circulating CD34 + cells, CD34 dim (JAM Visser and P Rubinstein, personal communication). The number of progenitor cells present in the fetal blood was determined in this study as CFC content. The data presented indicate that the blood of the ␣-thal-1 fetus, unlike the blood of fetuses with anemia due to other causes, contains a number of progenitor cells comparable to the number observed in normal blood. They also indicate that the paternal cells injected into the fetus were detectable soon (15 min) after the transplant and were viable after the injection. However, in every single transfusion performed the theoretical number of adult CFC injected was lower than the corresponding theoretical number of fetal cells present in the circulation (Table 2) . Since in the mouse, engraftment in the absence of myelosuppression is achieved by injecting a number of stem cells at least 10 2 -10 3 higher than those present in the marrow of the host, 26 it is concluded that the paternal CD34 + cells did not have a numerical advantage when injected into the ␣-thal-1 fetus. It is possible that, as suggested by Golfier et al, 32 the stem cells present in fetal bone marrow may represent, due to their fetal-like biological properties, a better source of stem cells than adult CD34
+ cells for in utero transplantation.
